Trial Type: Pancreas Cancer

LS-P-GO44479
LS-P-GO44479: A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran plus Atezolizumab and mFolfirinox versus mFolfirinox Alone in Patients with Respected Pancreatic Ductal Adenocarcinoma
Status: Open
Trial Type: Pancreas Cancer
Contact: Dr. Alex Raufi
araufi2@lifespan.org
LS-P-Poppy
LS-P-Poppy: First-in-class antibody-drug conjugate (ADC) targeting fibronectin (PYX-201) for solid tumors
Status: Open
Trial Type: Breast Cancer, Early Phase Trials for Multiple Cancer Types, Head and Neck Cancer, Kidney and Bladder Cancer, Lung Cancer, Ovarian Cancer, Pancreas Cancer, Soft Tissue and Bone Cancer
Contact: Dr. Benedito Carneiro
Benedito.carneiro@lifespan.org
CMC- Chemo4METPANC
Gemcitabine, nab-paclitaxel, cemiplimab and motixafortide for first line treatment of stage 4 pancreatic cancer.
Status: Open
Trial Type: Pancreas Cancer
Contact: Dr. Alex Raufi
araufi2@lifespan.org
LS-P-ARCH
A Randomized Phase II Trial of Nab-paclitaxel + Gemcitabine with or without Botensilimab for Metastatic Pancreatic Cancer Who Have Progressed on FOLFIRINOX
Status: Open
Trial Type: Pancreas Cancer
Contact: Dr. Alex Raufi
araufi2@lifespan.org

©2024 Brown Cancer Clinical Trials